logo
U.S.FDAApprovesExpandedIndicationforVONVENDI[vonWillebrandfactor(Recombinant)]forAdultsandChildrenwithVonWillebrandDisease
===2025/9/8 13:05:41===
the blood that are needed to facilitate proper blood clotting. Due to this defect or deficiency in VWF, blood is not able to clot effectively in people with VWD which may result in heavy menstrual periods, easy bruising, or frequent nose bleeds. Bleeding caused by VWD varies greatly among patients with this disease.2

About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employ
=*=*=*=*=*=
当前为第10/17页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页